Headlands Technologies LLC Has $648,000 Stake in Royalty Pharma plc (NASDAQ:RPRX)

Headlands Technologies LLC lowered its stake in shares of Royalty Pharma plc (NASDAQ:RPRX) by 2.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 23,085 shares of the biopharmaceutical company’s stock after selling 493 shares during the period. Headlands Technologies LLC’s holdings in Royalty Pharma were worth $648,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Truist Financial Corp purchased a new position in shares of Royalty Pharma in the 4th quarter worth approximately $443,000. Supplemental Annuity Collective Trust of NJ purchased a new position in shares of Royalty Pharma in the 4th quarter worth approximately $478,000. Stevens Capital Management LP purchased a new position in shares of Royalty Pharma in the 4th quarter worth approximately $375,000. NJ State Employees Deferred Compensation Plan purchased a new position in shares of Royalty Pharma in the 4th quarter worth approximately $674,000. Finally, Linden Thomas Advisory Services LLC boosted its stake in shares of Royalty Pharma by 7.5% in the 4th quarter. Linden Thomas Advisory Services LLC now owns 30,975 shares of the biopharmaceutical company’s stock worth $870,000 after buying an additional 2,152 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. JPMorgan Chase & Co. dropped their price objective on Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 20th. Bank of America dropped their price objective on Royalty Pharma from $40.00 to $38.00 and set a “buy” rating on the stock in a research note on Friday, April 12th. StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, April 11th. Finally, The Goldman Sachs Group dropped their price objective on Royalty Pharma from $56.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, February 20th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Royalty Pharma has an average rating of “Buy” and an average price target of $46.75.

Royalty Pharma Stock Performance

RPRX stock traded down $0.11 during midday trading on Friday, reaching $28.00. 1,748,254 shares of the company’s stock traded hands, compared to its average volume of 2,545,847. The firm has a market capitalization of $16.73 billion, a PE ratio of 14.81 and a beta of 0.45. Royalty Pharma plc has a 52 week low of $25.92 and a 52 week high of $35.76. The company has a 50-day moving average price of $29.61 and a two-hundred day moving average price of $28.55. The company has a debt-to-equity ratio of 0.61, a quick ratio of 7.90 and a current ratio of 7.90.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.12. The firm had revenue of $736.00 million for the quarter, compared to analysts’ expectations of $702.90 million. Royalty Pharma had a net margin of 48.22% and a return on equity of 26.93%. As a group, equities analysts anticipate that Royalty Pharma plc will post 3.95 EPS for the current year.

Royalty Pharma Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 17th will be paid a $0.21 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $0.84 dividend on an annualized basis and a yield of 3.00%. Royalty Pharma’s dividend payout ratio is presently 44.44%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.